Related Experiment Video
Updated: Feb 26, 2026

10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.0K
A Molecular Take on Malignant Rhabdoid Tumors
1Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Trends in Cancer
|July 26, 2017
Abstract:
The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular intertumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic, and epigenomic profiling. Distinct molecular subgroups were identified and new therapeutic targets were revealed.

